Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 9


A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells.

Sylvester JE, Kron SJ.

Mol Cancer Ther. 2010 May;9(5):1469-81. doi: 10.1158/1535-7163.MCT-10-0157. Epub 2010 Apr 27.


Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts.

Mand MR, Wu D, Veach DR, Kron SJ.

J Biomol Screen. 2010 Apr;15(4):434-40. doi: 10.1177/1087057110363307. Epub 2010 Mar 17.


Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.

Coluccia AM, Vacca A, Duñach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C.

EMBO J. 2007 Mar 7;26(5):1456-66. Epub 2007 Feb 22.


Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW.

Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71. Epub 2006 Oct 20.


Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Wendel HG, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW.

Proc Natl Acad Sci U S A. 2006 May 9;103(19):7444-9. Epub 2006 May 1.


Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads.

Wu D, Nair-Gill E, Sher DA, Parker LL, Campbell JM, Siddiqui M, Stock W, Kron SJ.

Anal Biochem. 2005 Dec 1;347(1):67-76. Epub 2005 Sep 22.


PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk